Savara (SVRA)

• Market cap: $1.13B
• 1 day: 2.23%
• 5 days: 4.36%
• 1 month: 12.02%
• 3 months: 9.13%
• 6 months: -9.24%
• Year to date: -2.48%
• 1 year: 165.7%
• 5 years: 210.73%
• 10 years: -81.68%
• Sector: Healthcare
• Industry: Biotechnology

About: Savara Inc is a clinical-stage biopharmaceutical company. It is focused on rare respiratory diseases. It has one segment specialty pharmaceuticals within the respiratory system. The company's main product candidate, molgramostim, is an inhaled granulocyte-macrophage colony-stimulating factor (GM-CSF) in Phase 3 development for autoimmune pulmonary alveolar proteinosis (aPAP).

Employees: 70